Factors that contribute to loss to follow-up in the medium term after initiation of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in Japanese patients.

Factors that contribute to loss to follow-up in the medium term after initiation of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in Japanese patients.

Show other versions (1)

<h4>Purpose</h4>To identify time-specific factors associated with loss to follow-up (LTFU) in the early to medium term after initiating anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD) in Japan.<h4>Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Takaaki Sugisawa, Fumi Gomi, Yuri Harada, Hiroko Imaizumi, Shuichiro Aoki, Akiko Miki, Maya Kishi, Tomofusa Yamauchi, Daisuke Nagasato, Yoko Ozawa, Masatoshi Haruta, Nobuhiro Kato, Hisashi Matsubara, Tsutomu Yasukawa, Aki Kato, Hiroto Terasaki, Takao Hirano, Yasuhiro Iesato, Hiroki Tsujinaka, Tomoya Murakami, Yoshinori Mitamura, Makiko Wakuta, Kazuhiro Kimura, Masahiko Shimura, J-CREST (Japan Clinical Retina Study) Group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0325963
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:<h4>Purpose</h4>To identify time-specific factors associated with loss to follow-up (LTFU) in the early to medium term after initiating anti-vascular endothelial growth factor (VEGF) treatment in patients with neovascular age-related macular degeneration (nAMD) in Japan.<h4>Methods</h4>The study had a retrospective multicenter case-control design and was performed across 16 specialist retinal facilities in Japan. Patients diagnosed with nAMD at their initial visit who initiated treatment between January 2017 and December 2020 were included. Patient characteristics were analyzed to identify factors associated with LTFU within 3 months (very early), 3 months to 1 year (early), and 1 year to 2 years (medium term) after starting treatment.<h4>Results</h4>Data for 2389 patients with nAMD were analyzed. The very early, early, and medium-term LTFU rates were 6.8%, 13.8%, and 21.2%, respectively. Stepwise regression analysis identified factors that were significantly associated with LTFU at a very early stage to be greater central retinal thickness at baseline and a prior treatment history, those associated with early LTFU to be worse baseline best-corrected visual acuity (BCVA), anti-VEGF treatment combined with photodynamic therapy, and a follow-up period that overlapped with the COVID-19 pandemic, and that associated with medium-term LTFU to be worse BCVA at 3 months. LTFU in any period within 3 months to 2 years was more likely in patients aged >80 years, and LTFU very early within 3 months was more likely in those aged <60 years. A poor baseline BCVA (logMAR) of >1 was a risk factor for LTFU within 3 months and 1 year, whereas LTFU was significantly less likely in patients with good baseline BCVA (<0.1).<h4>Conclusion</h4>The LTFU rate in patients with nAMD increased over time. Factors contributing to LTFU vary depending on the time since initiation of treatment.
ISSN:1932-6203

Similar Items